Antibody-to-imaging pipeline to monitor target engagement in breast tumors (Conference Presentation)
We established an antibody-to-imaging pipeline using near-infrared fluorescence lifetime (FLI) Forster Resonance Energy Transfer (FRET) imaging to quantify drug delivery and drug-receptor binding in HER2+ tumor xenografts. FLI FRET is a unique optical imaging modality for measuring antibody-target engagement in tumors in live, whole animal models.
Authors
- Xavier Intes (ORCID: https://orcid.org/0000-0001-5868-4845)
- Margarida Barroso (ORCID: https://orcid.org/0000-0002-0407-3181)
- Tynan Young (ORCID: https://orcid.org/0000-0002-3982-1485)
- Amit K. Verma (ORCID: https://orcid.org/0000-0001-7592-7693)
- Vikas Pandey (ORCID: https://orcid.org/0000-0001-5477-1095)
- Nanxue Yuan
- John Williams
- Cay Sherry
Institutions
- City Of Hope National Medical Center (US)
- Rensselaer Polytechnic Institute (US)
- City of Hope (US)
- Albany Medical Center Hospital (US)
Publication Details
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1117/12.3041505
- Primary Topic
- Advanced Biosensing Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00